KBC Group NV Purchases 170,416 Shares of Solventum Corporation $SOLV

KBC Group NV lifted its position in Solventum Corporation (NYSE:SOLV) by 36.9% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 632,833 shares of the company’s stock after purchasing an additional 170,416 shares during the period. KBC Group NV’s holdings in Solventum were worth $41,324,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Independent Franchise Partners LLP increased its position in Solventum by 19.0% during the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock valued at $1,216,785,000 after acquiring an additional 2,456,451 shares during the last quarter. Norges Bank bought a new position in Solventum in the fourth quarter valued at about $147,467,000. Diamond Hill Capital Management Inc. lifted its holdings in Solventum by 152.2% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after acquiring an additional 1,272,921 shares during the period. Boston Partners boosted its position in Solventum by 26.1% in the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after purchasing an additional 959,543 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Solventum by 20.0% in the fourth quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock worth $362,375,000 after purchasing an additional 763,308 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $91.00 price target on shares of Solventum in a research report on Monday, July 13th. BMO Capital Markets initiated coverage on shares of Solventum in a report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price objective on the stock. Rothschild & Co Redburn began coverage on shares of Solventum in a research report on Tuesday, March 24th. They set a “sell” rating and a $60.00 target price for the company. KeyCorp boosted their target price on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, UBS Group cut shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a report on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Solventum currently has an average rating of “Hold” and a consensus target price of $81.91.

Solventum Price Performance

NYSE SOLV opened at $79.22 on Tuesday. The company has a market capitalization of $13.72 billion, a PE ratio of 9.71, a price-to-earnings-growth ratio of 1.25 and a beta of 0.66. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The business’s fifty day moving average is $77.20 and its 200 day moving average is $74.22. Solventum Corporation has a fifty-two week low of $62.38 and a fifty-two week high of $88.20.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.Solventum’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Sell-side analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.